Cannabidiol and Autonomic Function at Rest

NCT ID: NCT04731779

Last Updated: 2023-05-15

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: EARLY_PHASE1
• Total Enrollment: 18 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-08-30
• Study Completion Date: 2021-11-29

Brief Summary

Cannabidiol (CBD) is one of 700 chemicals derived from the Cannabis sativa plant and is both legal and widespread for distribution in the state of Vermont. The central hypothesis of this proposal is that in apparently healthy adults, acute CBD favorably affects the autonomic nervous system and that this will be evident by an increase in heart rate variability. The overall goal is to understand how CBD affects the autonomic and cardiovascular systems at rest, and when perturbed. The investigators will study a narrow age range of adults, administer varying acute doses of CBD, characterize baseline cardiovascular variables, and record responses to autonomic challenge maneuvers. This will provide the framework to assess potential therapies and/or risk factors of CBD, particularly as it relates to healthy individuals. More information that is so widely taken, especially one that targets receptors known to be involved in cardiovascular signaling pathways is imperative.

Detailed Description

The study will be conducted in the Exercise Physiology Laboratory in the Jeffords Science Building at Castleton University. Participants will be asked to fast overnight, avoid beverages or food containing caffeine, alcohol, or CBD for at least 12h, and to not perform physical effort for 6h prior to each session.

During the initial session, individuals will: have their height and body mass measured, complete a health history questionnaire, and sign a consent form approved by Castleton University's Institutional Review Board. Prior to data collection, individuals will be advised of the possible risks, methods, and potential benefits of this study. They will also be familiarized with the noninvasive cardiovascular monitoring equipment, which they will be putting on themselves. These include an automated blood pressure (BP) cuff and a heart rate (HR) chest strap monitor.

On the day of each experiment, participants will be given a standardized meal and asked to put on the BP cuff and HR monitor. Individuals will remain seated for the length of the experiment (doing nothing or reading). Baseline measurements will be taken remotely following 15 minutes of rest. Under supervision, participants will be asked to consume oral CBD oil (0mg, 25 mg, 50 mg, or 200mg), infused in non-CBD containing MCT (medium-chain triglycerides) oil to standardize dose volume of 3ml. Assessments will be measured remotely at intervals up to 2.5 hours after ingestion. The study will be double-blind, thus neither the participant nor researcher will be aware of the CBD dose for a particular session. Participants will be asked to return for 3 additional consecutive weeks, each session will be a different dose of CBD.

In the final experimental session (to be completed after initial analyses of dose responses), participants will be given a standardized meal and asked to put on the blood pressure cuff and HR monitors. Individuals will remain seated for the length of the experiment. Following 15 minutes of rest, participants will be asked to perform two autonomic stress tests: the isometric hand grip test, and the cold face test. First, the maximum voluntary contraction (MVC) for the isometric hand grip test will be assessed. Participants will be asked to press a handgrip dynamometer with full strength. To perform the isometric handgrip test, participants will again use the dynamometer and maintain handgrip at 30 percent MVC for 2 min. A recovery period of 10 minutes between each test will be observed. For the cold face test, a cold compress (1-2 degrees Celcius) will be applied to the forehead and maxillary region of the subjections face for 2 min. Following these baseline tests, participants will be asked to consume a dose of CBD (determined following analyses of the initial 4 sessions) and perform the two autonomic stress tests again 2h post ingestion.

Conditions

Healthy

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: TRIPLE

Study Groups

Placebo

Participants will ingest 3ml of non-CBD containing MCT (medium-chain triglycerides) oil.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Placebo oral product formulated in MCT (medium chain triglyceride) oil

25 mg

Participants will ingest 3ml of MCT (medium-chain triglycerides) oil containing 25 mg of CBD.

Group Type: EXPERIMENTAL

cannabidiol

Intervention Type: DRUG

Cannabidiol oral product formulated in MCT (medium chain triglyceride) oil

50 mg

Participants will ingest 3ml of MCT (medium-chain triglycerides) oil containing 50 mg of CBD.

Group Type: EXPERIMENTAL

cannabidiol

Intervention Type: DRUG

Cannabidiol oral product formulated in MCT (medium chain triglyceride) oil

200 mg

Participants will ingest 3ml of MCT (medium-chain triglycerides) oil containing 200 mg of CBD.

Group Type: EXPERIMENTAL

cannabidiol

Intervention Type: DRUG

Cannabidiol oral product formulated in MCT (medium chain triglyceride) oil

Interventions

cannabidiol

Cannabidiol oral product formulated in MCT (medium chain triglyceride) oil

Intervention Type: DRUG

Placebo

Placebo oral product formulated in MCT (medium chain triglyceride) oil

Intervention Type: DRUG

Other Intervention Names

CBD

Eligibility Criteria

Inclusion Criteria

• Male or female, 18-35 years of age.
• Participants must agree to fast and abstain from food or beverages containing alcohol, caffeine, or CBD for 12 hours prior to each experimental session.
• Completion of Health History Questionnaire with report indicating overall good health.
• The ability to comprehend and satisfactorily comply with protocol requirements.
• Written informed consent given prior to beginning the study.

Exclusion Criteria

• Current medications that might influence the cardiovascular and/or autonomic systems.
• Women who are pregnant or lactating.
• Participants who have a history of adverse reactions to cannabidiol will be excluded.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 35 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Castleton University

OTHER

Sponsor Role: lead

Responsible Party

Andrea Corcoran

Assistant Professor of Exercise Science

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Castleton University, Jeffords Science Building

Castleton, Vermont, United States

Countries

United States

Other Identifiers

VRBN Pilot 2021_Corcoran

Identifier Type: -

Identifier Source: org_study_id